Drug Profile
Research programme: cancer diagnostics - Piramal HealthCare/Cancer Targeted Technology
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma; Cancer Targeted Technology
- Developer Bayer HealthCare Pharmaceuticals; Cancer Targeted Technology
- Class Diagnostic agents; Imaging agents; Small molecules
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer